SV

Street Verdict

Analyst Scorecard

SANOFI · NSE

Sanofi India Limited

₹3,206.1

+0.11% (+₹3.6)

Prev. close

₹3,202.5

Volume

8,473

Delivery %

50.1%

As of

20 Nov 2026

Price history

₹3,206.1-₹36 (-1.11%) · 3M
18 Aug 2026 → 20 Nov 2026
2,8002,9003,0003,1003,2003,3003,40018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Sanofi India Limited

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.

Details

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Deepak Arora

Headquarters

Mumbai

Employees

1,097

Key stats

Market cap

₹7,947.41 Cr

P/E ratio (TTM)

22.0

Dividend yield

3.64%

EPS (TTM)

₹156.78

Beta (1Y · daily vs NIFTY 50)

0.60

Beta (5Y · monthly vs NIFTY 50)

0.72

Shares float

90.73 L

EPS · quarter ended Sept 2026

₹50.67

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr₹0%10%20%30%40%Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0200400600₹Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025

03 · Dividend Profile

0200400600₹-250%0%250%500%29 Jun 2019 Apr 2112 Apr 2205 Aug 2228 Apr 2307 Mar 2403 May 2425 Apr 2507 Nov 2522 Apr 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: January–December (calendar year — this company reports on a December year-end), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0×0.5×1×1.5×Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr1000 Cr2000 Cr3000 Cr₹Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
₹2,956.60 Cr₹2,770.10 Cr₹1,981.60 Cr₹2,013.20 Cr₹1,823.40 Cr
EBITDA
₹1,326.10 Cr₹907.90 Cr₹569.80 Cr₹471.10 Cr₹483.70 Cr
₹944.40 Cr₹620.60 Cr₹602.90 Cr₹413.50 Cr₹326.70 Cr
Diluted EPS
₹410.06₹269.47₹261.78₹179.46₹141.85

Total expenses (as filed), Employee benefit expense, Other expenses, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemDec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
₹2,918.50 Cr₹3,061.00 Cr₹2,071.70 Cr₹1,714.80 Cr₹1,611.80 Cr₹1,254.80 Cr
₹22.60 Cr₹24.60 Cr₹23.60 Cr₹19.00 Cr₹19.30 Cr₹17.80 Cr
Stockholders' equity
₹2,119.00 Cr₹2,225.60 Cr₹1,275.80 Cr₹1,015.20 Cr₹860.60 Cr₹749.20 Cr

Fixed assets, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemDec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
—₹558.80 Cr₹398.70 Cr₹230.40 Cr₹461.50 Cr₹438.30 Cr
Investing cash flow
—₹630.80 Cr₹650.90 Cr₹37.50 Cr₹-19.20 Cr₹-11.30 Cr
—₹-849.00 Cr₹-1,582.70 Cr₹-878.30 Cr₹-392.40 Cr—
Capital expenditure
—₹-23.00 Cr₹-22.20 Cr₹-34.30 Cr₹-36.40 Cr₹-25.70 Cr
End cash position
₹1,197.40 Cr₹1,538.00 Cr₹1,004.90 Cr₹394.50 Cr₹283.80 Cr₹262.90 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Jun 26(20Q)
Promoter60.40%
Public39.60%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Sanofi India Limited₹7,788.04 Cr₹3,450.821.410.4043.6%0.02-8.3%-27.4%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

Index membership

1 index

SANOFI

Sanofi Explores Potential USD 26.28 Billion Acquisition of Insmed: Bloomberg

Medical Dialogues · 2 days ago

SANOFI

Sanofi India stock: Q3 profit rises 54% as dividend declared

ad-hoc-news.de · 17 days ago